Lytix Biopharma is pleased to announce that the 1^st cohort of LTX-315 3 mg in combination with anti-PD1 treatment (pembrolizumab) administered at standard approved dose and schedule is completed. Three patients completed all planned 3 weeks of LTX-315 treatment in combination with pembrolizumab with no clinically significant LTX-315 related adverse events or dose-limiting toxicities observed. A new, higher dose (4 mg) cohort in TNBC has recently been initiated.

 

Andrew Saunders, CMO of Lytix Biopharma commented:

‘We are very pleased that combining LTX-315 with pembrolizumab in TNBC appears safe and feasible and eagerly await completion of all planned dose cohorts in the coming months.”

Håkan Wickholm, CEO of Lytix Biopharma commented:

“TNBC represents a patient population with a major unmet need and there is a strong rationale to combine LTX-315 with anti-PD1 with the potential for significant clinical benefit.”

 

It is well known that response rates in immune therapy in cancer are higher when immune effector cells are present in the tumour microenvironment. When the tumour lacks immune effector cells, they are termed “cold” and when immune effector cells are present they are termed “hot”. Preclinical studies have shown that Lytix Biopharma’s compound LTX-315 has the potential to make cold tumours hot and thus increase the overall patient response of combinations with other cancer treatments.

These studies and Phase I trials forms the basis for evaluating LTX-315 in combination with immune checkpoint inhibitors, anti-CTLA4 and anti-PD1, in metastatic melanoma patients treated with prior anti-PD1 therapy and previously treated metastatic triple negative breast cancer (TNBC) patients.